Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1021/ACS.BIOMAC.3C01444 | ||||
| Año | 2024 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
3D-printed hydrogel scaffolds biomimicking the extracellular matrix (ECM) are key in cartilage tissue engineering as they can enhance the chondrogenic differentiation of mesenchymal stem cells (MSCs) through the presence of active nanoparticles such as graphene oxide (GO). Here, biomimetic hydrogels were developed by cross-linking alginate, gelatin, and chondroitin sulfate biopolymers in the presence of GO as a bioactive filler, with excellent processability for developing bioactive 3D printed scaffolds and for the bioprinting process. A novel bioink based on our hydrogel with embedded human MSCs presented a cell survival rate near 100% after the 3D bioprinting process. The effects of processing and filler concentration on cell differentiation were further quantitatively evaluated. The nanocomposited hydrogels render high MSC proliferation and viability, exhibiting intrinsic chondroinductive capacity without any exogenous factor when used to print scaffolds or bioprint constructs. The bioactivity depended on the GO concentration, with the best performance at 0.1 mg mL(-1). These results were explained by the rational combination of the three biopolymers, with GO nanoparticles having carboxylate and sulfate groups in their structures, therefore, biomimicking the highly negatively charged ECM of cartilage. The bioactivity of this biomaterial and its good processability for 3D printing scaffolds and 3D bioprinting techniques open up a new approach to developing novel biomimetic materials for cartilage repair.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | OLATE-MOYA, FELIPE ANDRES | Hombre |
Universidad de Chile - Chile
Ctr Intervent Med Precis & Adv Cellular Therapy - Chile IMPACT - Chile |
| 2 | Rubi-Sans, Gerard | - |
Barcelona Inst Sci & Technol BIST - España
CIBER BBN - España Instituto de Bioingeniería de Cataluña - España BBN Technologies - Estados Unidos |
| 3 | Engel, Elisabeth | Mujer |
Barcelona Inst Sci & Technol BIST - España
CIBER BBN - España Univ Politecn Catalunya UPC - España Universitat Politècnica de Catalunya - España Instituto de Bioingeniería de Cataluña - España BBN Technologies - Estados Unidos |
| 4 | Mateos-Timoneda, Miguel Angel | Hombre |
Univ Int Catalunya - España
Universitat Internacional de Catalunya - España |
| 5 | PALZA-CORDERO, HUMBERTO CRISTIAN | Hombre |
Universidad de Chile - Chile
Ctr Intervent Med Precis & Adv Cellular Therapy - Chile IMPACT - Chile |
| Fuente |
|---|
| European Regional Development Fund |
| Generalitat de Catalunya |
| Ministerio de Ciencia, Innovacion y Universidades |
| Agencia Estatal de Investigación |
| FEDER, UE |
| Fondo Nacional de Desarrollo Cient?fico y Tecnol?gico |
| Agencia Nacional de Investigación y Desarrollo |
| PRTR |
| European Union's Horizon Europe research and innovation programme |
| Union Europea NextGenerationEU/PRTR |
| European Union’s Horizon Europe research and innovation programme |
| Unión Europea NextGenerationEU |
| ANID-Basal Center of Interventional Medicine for Precision and Advanced Cellular Therapy, IMPACT |
| ANID under FONDEQUIP Projects |
| Icrea Academia 2022 |
| Severo Ochoa Unit of Excellence |
| Programme/Generalitat de Catalunya |
| Programme |
| Agradecimiento |
|---|
| The authors are thankful for the financial support from ANID under FONDEQUIP Projects EQM150101 and EQM140012 and project ANID-Basal Center of Interventional Medicine for Precision and Advanced Cellular Therapy, IMPACT, # FB210024. F.O.M. thanks ANID (ex CONICYT) Beca de Doctorado Nacional 21150039 and FONDECYT de Postdoctorado 3240135. E.E. thanks the European Union's Horizon Europe research and innovation programme under grant agreement No. 101098972 (BIOACTION), Programme/Generalitat de Catalunya (2021 SGR 00387) and Severo Ochoa Unit of Excellence (CEX2018-000, 789-S, 2019-2023) and Icrea Academia 2022. M.A.M.T. thanks MICIU/AEI 10.13039/501100011033 and FEDER, UE for funding project PID2022-137962OB-I00, MICIU/AEI/10.13039/501100011033 and Union Europea NextGenerationEU/PRTR for funding project PLEC2022-009279, and Programme/Generalitat de Catalunya (2021 SGR 00565). The TOC graphic was created using BioRender. |
| The authors are thankful for the financial support from ANID under FONDEQUIP Projects EQM150101 and EQM140012 and project ANID-Basal Center of Interventional Medicine for Precision and Advanced Cellular Therapy, IMPACT, # FB210024. F.O.M. thanks ANID (ex CONICYT) Beca de Doctorado Nacional 21150039 and FONDECYT de Postdoctorado 3240135. E.E. thanks the European Union\u2019s Horizon Europe research and innovation programme under grant agreement No. 101098972 (BIOACTION), Programme/Generalitat de Catalunya (2021 SGR 00387) and Severo Ochoa Unit of Excellence (CEX2018-000, 789-S, 2019-2023) and Icrea Academia 2022. M.A.M.T. thanks MICIU/AEI 10.13039/501100011033 and FEDER, UE for funding project PID2022-137962OB-I00, MICIU/AEI/10.13039/501100011033 and Unio\u0301n Europea NextGenerationEU/PRTR for funding project PLEC2022-009279, and Programme/Generalitat de Catalunya (2021 SGR 00565). The TOC graphic was created using BioRender. |